PRPO logo

Precipio (PRPO) Stock

Profile

Sector:

Healthcare

Country:

United States

IPO:

30 June 2017

Indexes:

Not included

Description:

Precipio (PRPO) is a biotechnology company focused on developing innovative cancer therapies. They use advanced technology to create personalized treatments that target specific cancer cells, aiming to improve patient outcomes and reduce side effects. Their goal is to make cancer care more effective and tailored to individual needs.

Events Calendar

Earnings

Next earnings date:

Apr 01, 2025

Recent quarterly earnings:

Nov 18, 2024

Recent annual earnings:

Apr 01, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Sept 22, 2023

Analyst ratings

Recent major analysts updates

25 Nov '20 Maxim Group
Buy
22 Nov '19 Maxim Group
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Precipio, Inc. (PRPO) Q3 2024 Earnings Call Transcript
Precipio, Inc. (PRPO) Q3 2024 Earnings Call Transcript
Precipio, Inc. (PRPO) Q3 2024 Earnings Call Transcript
PRPO
seekingalpha.com18 November 2024

Precipio, Inc. (NASDAQ:PRPO ) Q3 2024 Earnings Conference Call November 18, 2024 5:00 PM ET Company Participants Ilan Danieli - CEO Conference Call Participants Operator Good day. Welcome to the Precipio Third Quarter 2024 Shareholder Update Conference Call.

Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping
Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping
Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping
PRPO
globenewswire.com08 October 2024

The unique assay enables laboratories to provide clinicians with more informed treatment decisions for their patients The unique assay enables laboratories to provide clinicians with more informed treatment decisions for their patients

Precipio Announces Employee Stock Option Plan Repricing
Precipio Announces Employee Stock Option Plan Repricing
Precipio Announces Employee Stock Option Plan Repricing
PRPO
globenewswire.com06 September 2024

NEW HAVEN, Conn., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company  Precipio, Inc.   (NASDAQ: PRPO) announces the Company's repricing of a portion of its employee stock options to ensure their effectiveness as a retention tool for valuable employees.

Precipio, Inc. (PRPO) Q2 2024 Earnings Call Transcript
Precipio, Inc. (PRPO) Q2 2024 Earnings Call Transcript
Precipio, Inc. (PRPO) Q2 2024 Earnings Call Transcript
PRPO
seekingalpha.com19 August 2024

Precipio, Inc. (NASDAQ:PRPO ) Q2 2024 Earnings Conference Call August 19, 2024 5:00 PM ET Company Participants Ilan Danieli - Chief Executive Officer Operator Welcome to the Precipio Second Quarter 2024 Shareholder Update Conference Call. All participants will be in a listen-only mode.

Precipio Announces Q2-2024 Shareholder Update Call
Precipio Announces Q2-2024 Shareholder Update Call
Precipio Announces Q2-2024 Shareholder Update Call
PRPO
globenewswire.com15 August 2024

NEW HAVEN, Conn., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company  Precipio, Inc.   (NASDAQ: PRPO) , will be hosting its Q2-2024 corporate update call on August 19th at 5:00 PM ET.

Precipio Reports $4.4M for Q2-2024 (unaudited) Revenues, a leap of 30% from Q1-2024
Precipio Reports $4.4M for Q2-2024 (unaudited) Revenues, a leap of 30% from Q1-2024
Precipio Reports $4.4M for Q2-2024 (unaudited) Revenues, a leap of 30% from Q1-2024
PRPO
globenewswire.com17 July 2024

Pathology Revenues in June exceed breakeven target and continue growth trend Pathology Revenues in June exceed breakeven target and continue growth trend

Precipio Inc. Announces Adjournment of Annual Meeting of Stockholders
Precipio Inc. Announces Adjournment of Annual Meeting of Stockholders
Precipio Inc. Announces Adjournment of Annual Meeting of Stockholders
PRPO
globenewswire.com13 June 2024

New Shareholders Meeting Date: Friday, June 21 at 9 a.m. Eastern Time New Shareholders Meeting Date: Friday, June 21 at 9 a.m. Eastern Time

Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
PRPO
globenewswire.com12 June 2024

NEW HAVEN, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company  Precipio, Inc.   (NASDAQ: PRPO) is requesting that shareholders instruct their brokers to vote their shares immediately today no later than 11pm Eastern Time.

Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY
Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY
Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY
PRPO
GlobeNewsWire13 February 2024

NEW HAVEN, Conn., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces that for the full year of 2023, its unaudited revenues have grown from $9.4M in 2022 to $15.2M in 2023, an increase of 60% year over year.

Precipio, Inc. (PRPO) Q3 2023 Earnings Call Transcript
Precipio, Inc. (PRPO) Q3 2023 Earnings Call Transcript
Precipio, Inc. (PRPO) Q3 2023 Earnings Call Transcript
PRPO
Seeking Alpha20 November 2023

Precipio, Inc. (NASDAQ:PRPO ) Q3 2023 Earnings Conference Call November 20, 2023 5:00 PM ET Company Participants Ilan Danieli - Chief Executive Officer Operator Welcome to the Precipio Third Quarter 2023 Shareholder Update Conference Call. All participants will be in listen-only mode.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the primary business of Precipio?
  • What is the ticker symbol for Precipio?
  • Does Precipio pay dividends?
  • What sector is Precipio in?
  • What industry is Precipio in?
  • What country is Precipio based in?
  • When did Precipio go public?
  • Is Precipio in the S&P 500?
  • Is Precipio in the NASDAQ 100?
  • Is Precipio in the Dow Jones?
  • When was Precipio's last earnings report?
  • When does Precipio report earnings?
  • Should I buy Precipio stock now?

What is the primary business of Precipio?

Precipio (PRPO) is a biotechnology company focused on developing innovative cancer therapies. They use advanced technology to create personalized treatments that target specific cancer cells, aiming to improve patient outcomes and reduce side effects. Their goal is to make cancer care more effective and tailored to individual needs.

What is the ticker symbol for Precipio?

The ticker symbol for Precipio is NASDAQ:PRPO

Does Precipio pay dividends?

No, Precipio does not pay dividends

What sector is Precipio in?

Precipio is in the Healthcare sector

What industry is Precipio in?

Precipio is in the Diagnostics & Research industry

What country is Precipio based in?

Precipio is headquartered in United States

When did Precipio go public?

Precipio's initial public offering (IPO) was on 30 June 2017

Is Precipio in the S&P 500?

No, Precipio is not included in the S&P 500 index

Is Precipio in the NASDAQ 100?

No, Precipio is not included in the NASDAQ 100 index

Is Precipio in the Dow Jones?

No, Precipio is not included in the Dow Jones index

When was Precipio's last earnings report?

Precipio's most recent earnings report was on 18 November 2024

When does Precipio report earnings?

The next expected earnings date for Precipio is 1 April 2025

Should I buy Precipio stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions